Title:Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning
Volume: 25
Issue: 33
Author(s): Md. Tanvir Kabir, Md. Sahab Uddin*, Mst. Marium Begum, Shanmugam Thangapandiyan, Md. Sohanur Rahman, Lotfi Aleya, Bijo Mathew, Muniruddin Ahmed, George E. Barreto and Ghulam Md. Ashraf
Affiliation:
- Department of Pharmacy, Southeast University, Dhaka,Bangladesh
Keywords:
Acetylcholine, acetylcholinesterase inhibitors, tacrine, donepezil, galantamine, rivastigmine, Alzheimer’s disease.
Abstract: In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement
of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction
and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement
of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement
in AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting
peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic
target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the
symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to be
developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper,
we summarize the different types of ChEIs which are under development and their respective mechanisms of
actions.
